Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Associate Director, Immunosafety and Bioanalytical Development at Editas Medicine
Junxia Wang, is an Associate Director of Immunosafety and Bioanalytical development at Editas Medicine, responsible for the development and implementation of strategies for safety evaluation CRISPR/Cas9 programs across portfolio with a focus on immunogenicity. Prior to Editas, Junxia worked at Novartis, where she was a Fellow in Cell and Gene Therapy, Oncology Business Unit, a project leader in Technical Research and Development spearheaded exploratory analytical activities for biomarker discovery, and led functional assay design and development to support process development, manufacturing and clinical development of CAR T-Cell immunotherapy. Before Novartis, Junxia was an Instructor and Associate Immunologist in Division of Rheumatology, Immunology and Allergy at Brigham and Women’s, where she conducted research on biomarkers/targets for Inflammatory Arthritis in human using CyTOF, human T cell immuno-phenotyping, classification of T cell effector and memory subsets with PD1 expression. Junxia received her Ph.D. in Pharmacology at Shanghai Institute of Materia Medica, Chinese Academy of Sciences.